Zhixiong Zhu

Zhixiong Zhu

Auto-generated profile, based on publicly available information

Zhixiong Zhu

State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Bispecific antibodies (BsAb) and antibody-drug conjugates (ADC) have shown significant promise in cancer treatment, enhancing drug selectivity and therapeutic efficacy as demonstrated in multiple clinical studies. Bispecific antibody-drug conjugates (BsADC), which combine the targeting capabilities of BsAbs with the cytotoxic potential of ADCs, offer a novel approach to overcoming several challenges associated with ADCs, including limited internalization, off-target toxicity, and drug resistance. In this study, we identified solute carrier family 3 member 2 (SLC3A2) as a highly expressed protein in a variety of solid tumors, making it a promising therapeutic target. We developed a BsAb targeting SLC3A2 and PD-L1 and conjugated it to monomethyl auristatin E (MMAE) to create the SLC3A2/PD-L1 BsADC. The SLC3A2/PD-L1 BsAb effectively blocked PD-1 binding to PD-L1 and activated T cells while also facilitating lysosomal targeting and degradation of poorly internalized PD-L1 antibodies. The SLC3A2/PD-L1 BsADC demonstrated superior antitumor efficacy in PD-L1 low-expressing tumor cells compared with single-target ADCs in both in vitro studies and in multiple xenograft and immunocompetent mouse models. Overall, our engineered SLC3A2/PD-L1 BsADC exhibited enhanced internalization and improved tumor cell targeting, highlighting the potential of lysosome-targeting BsAbs in advancing ADC therapeutic strategies for solid tumors.

4 February 2025
Verified
Other
Open access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Supplementary Figure 4. LC-MS analysis and average DAR value of antibody-drug conjugates. A, LC-MS analysis of SLC3A2/PD-L1 BsADC. LC-MS, liquid chromatography-MS. The average DAR of SLC3A2/PD-L1 BsADC was 0.82. B, LC-MS analysis of SLC3A2 ADC. The average DAR of SLC3A2/PD-L1 BsADC was 1.63. C, LC-MS analysis of PD-L1 ADC. The average DAR of PD-L1 ADC was 0.93.

4 February 2025
Verified
Other
Open access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Supplementary Figure 5. Flow cytometry analysis for apoptosis. A, Flow cytometric analysis for cell apoptosis in SNU-899 cells. B, Flow cytometric analysis for cell apoptosis in H460 cells. C, Flow cytometric analysis for cel

4 February 2025
Verified
Other
Open access
ZWZeng Wang
Zeng Wang
MZMeijun Zheng
Meijun Zheng
MLMengyao Li
Mengyao Li
HLHuaqing Lu
Huaqing Lu
NLNanxi Liu
Nanxi Liu
ATAiping Tong
Aiping Tong
Supplementary Figure 2. Specific targeting of anti-SLC3A2 19G4 mAb and anti-PD-L1 mAb. A, Sequencing results for HeLa SLC3A2KO cells using CRISPR/Cas9 technology. B, Flow cytometry analysis of 19G4 mAb specific binding to SLC3A2 in HeLa-WT and HeLa-SLC3A2KO cell lines. C, Flow cytometry analysis of 2217B3 mAb specific binding to PD-L1 in HeLa-WT and HeLa-PD-L1 cell lines. D, Flow cytometry analysis of 19G4 mAb binding to SLC7A5 and mouse SLC3A2. E, Flow cytometry analysis of 2217B3 mAb binding to PD-1 and mouse PD-L1.

8 September 2026 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ZZZhixiong Zhu
Zhixiong Zhu
JLJia Li
Jia Li
HLHexian Li
Hexian Li
QLQizhong Lu
Qizhong Lu
ZYZhengyu Yu
Zhengyu Yu
Messenger RNA (mRNA) therapeutics have evolved from a technically constrained modality into a clinically validated platform for vaccination that is increas